Janssen Hits Back At Sandoz In IP Battle Over Cancer Drug
A subsidiary of Johnson & Johnson has fought back against a suit from generic-drug maker Sandoz seeking to invalidate its prostate cancer drug, saying that the patent clearly set out the...To view the full article, register now.
Already a subscriber? Click here to view full article